 Pyrans
"Pyrans" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D011714
|
| MeSH Number(s) |
D03.383.663 D03.830
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrans".
Below are MeSH descriptors whose meaning is more specific than "Pyrans".
This graph shows the total number of publications written about "Pyrans" by people in UAMS Profiles by year, and whether "Pyrans" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2021 | 2 | 0 | 2 | | 2020 | 0 | 1 | 1 | | 2019 | 1 | 0 | 1 | | 2016 | 0 | 1 | 1 | | 2013 | 1 | 0 | 1 | | 2012 | 0 | 1 | 1 | | 1999 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Pyrans" by people in Profiles over the past ten years.
-
Yu H, Liu X, Chen B, Vickstrom CR, Friedman V, Kelly TJ, Bai X, Zhao L, Hillard CJ, Liu QS. The Neuroprotective Effects of the CB2 Agonist GW842166x in the 6-OHDA Mouse Model of Parkinson's Disease. Cells. 2021 12 16; 10(12).
-
Urbaniak A, Reed MR, Fil D, Moorjani A, Heflin S, Antoszczak M, Sulik M, Huczynski A, Kupsik M, Eoff RL, MacNicol MC, Chambers TC, MacNicol AM. Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models. Biomed Pharmacother. 2021 Sep; 141:111815.
-
Urbaniak A, Pi?a-Oviedo S, Yuan Y, Huczynski A, Chambers TC. Limitations of an ex vivo breast cancer model for studying the mechanism of action of the anticancer drug paclitaxel. Eur J Pharmacol. 2021 Jan 15; 891:173780.
-
Czerwonka D, Urbaniak A, Sobczak S, Pi?a-Oviedo S, Chambers TC, Antoszczak M, Huczynski A. Synthesis and Anticancer Activity of Tertiary Amides of Salinomycin and Their C20-oxo Analogues. ChemMedChem. 2020 01 17; 15(2):236-246.
-
Kim RD, Sarker D, Meyer T, Yau T, Macarulla T, Park JW, Choo SP, Hollebecque A, Sung MW, Lim HY, Mazzaferro V, Trojan J, Zhu AX, Yoon JH, Sharma S, Lin ZZ, Chan SL, Faivre S, Feun LG, Yen CJ, Dufour JF, Palmer DH, Llovet JM, Manoogian M, Tugnait M, Stransky N, Hagel M, Kohl NE, Lengauer C, Sherwin CA, Schmidt-Kittler O, Hoeflich KP, Shi H, Wolf BB, Kang YK. First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. Cancer Discov. 2019 12; 9(12):1696-1707.
-
Antoszczak M, Urbaniak A, Delgado M, Maj E, Borgstr?m B, Wietrzyk J, Huczynski A, Yuan Y, Chambers TC, Strand D. Biological activity of doubly modified salinomycin analogs - Evaluation in?vitro and ex?vivo. Eur J Med Chem. 2018 Aug 05; 156:510-523.
-
Urbaniak A, Delgado M, Antoszczak M, Huczynski A, Chambers TC. Salinomycin derivatives exhibit activity against primary acute lymphoblastic leukemia (ALL) cells in vitro. Biomed Pharmacother. 2018 Mar; 99:384-390.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|